Portfolio
Astrocyte Pharmaceuticals is currently investigating several programs for the potential treatment of acute ischemic stroke, TBI, concussion, and other injuries to the brain.
The company’s lead candidate program AST-004 is a novel small molecule candidate currently in human Phase I clinical safety trials with an intravenous injection formulation suitable for administration by emergency professionals. An oral “field” formulation of AST-004 for mild TBI and concussions, and for chronic administration for neurodegenerative diseases is in preclinical development.
Candidate
Indication
Preclinical
Phase 1
Phase 2
Phase 3
AST-004
Acute Ischemic Stroke
AST-004
Severe-Moderate TBI
AST-004
Concussion / Mild TBI
AST-004
Alzheimer’s Disease
AST-008
Pain / Migraine
undisclosed
Multiple CNS Indications
Human Phase II patient clinical efficacy trials of AST-004 are planned to start in approximately a year, while subsequent Phase III studies, and New Drug Application (NDA) review by regulatory agencies such as the FDA typically take an additional 2-5 years to confirm results and approve the use of a new therapeutic.
